The Multidisciplinary Tumor Board: How Your Cancer Treatment Plan Is Made

When you are diagnosed with head and neck cancer, the decisions that follow are among the most important of your life. Which surgery is needed? Does radiation come first, or after? What about chemotherapy? These questions rarely have a single obvious answer, and the right plan depends on details that no one specialist can fully evaluate alone. This is why, before your treatment begins, your case is almost certainly being discussed by a group of specialists who have never met you — a team whose sole purpose is to examine your cancer from every angle and arrive at a recommendation that reflects the full weight of current evidence. That group is the multidisciplinary tumor board, and understanding how it works can help you feel more confident about the plan you receive.

What Is a Tumor Board?

A multidisciplinary tumor board is a formal, scheduled conference in which specialists from different disciplines review a patient's imaging, pathology, and clinical findings together and reach a consensus on treatment. At Aurora St. Luke's, I attend a dedicated head and neck tumor board every week alongside radiation oncologists, medical oncologists, radiologists, pathologists, and speech-language pathologists. Every new head and neck cancer diagnosis I see — and many recurrences or complex cases already in treatment — gets presented at that conference before we finalize a treatment plan.

Who Is in the Room

The value of a tumor board comes from the range of expertise it assembles. Here is who is typically present and what each specialist contributes:

Surgical oncology (head and neck surgery): I present the case — what the tumor looks like on exam, the functional structures involved, what surgical resection would require, and what reconstruction is feasible. I also weigh in on whether surgery or radiation is the better primary treatment modality given the specific location and stage.

Radiation oncology: The radiation oncologist evaluates whether radiation alone, radiation combined with chemotherapy (chemoradiation), or postoperative radiation is indicated. For some cancers — particularly early-stage larynx cancers and some oropharyngeal tumors — radiation-based treatment is preferred over surgery, and this expertise is essential to that determination.

Medical oncology: The medical oncologist assesses whether systemic therapy plays a role: concurrent chemotherapy to sensitize the tumor to radiation, induction chemotherapy before definitive treatment, immunotherapy, or targeted therapy. They also manage toxicity during treatment.

Radiology: The radiologist reviews the CT, MRI, and PET scans in detail — evaluating tumor extent, lymph node involvement, vascular encasement, bone invasion, and distant metastases. Their read of the imaging directly informs resectability and staging.

Pathology: The pathologist reviews the biopsy results: tumor type, grade, margin status if surgery has already occurred, HPV or p16 status for oropharyngeal cancers, perineural invasion, and lymphovascular invasion. These details substantially affect treatment decisions.

Speech-language pathology and nutrition: For cancers affecting swallowing, speech, or airway, these specialists assess functional status before treatment and anticipate what rehabilitation will be needed afterward. Their early involvement improves long-term outcomes.

How the Conference Works

Cases are presented in sequence, usually with imaging displayed on a large screen in the conference room. The surgeon or referring physician summarizes the clinical history and examination findings. The radiologist walks through the scans. The pathologist reviews the biopsy. Then the group discusses.

The discussion is sometimes brief — a straightforward case with a clear standard-of-care recommendation. More often, it involves genuine deliberation. Does the imaging suggest the tumor abuts the carotid artery, and if so, does that change the surgical approach or even the feasibility of resection? Is the patient's baseline swallowing function good enough that they are likely to recover swallowing after the treatment being considered? Does the HPV-positive status of this oropharynx tumor make them a candidate for a de-escalated treatment approach? Is reconstruction with a free flap necessary, and if so, which donor site is most appropriate?

At the end of the discussion, the group reaches a recommendation. That recommendation is what I bring back to the patient.

Why This Matters for Your Care

Patients sometimes ask me: "Can't you just tell me the plan?" I can, and I will — but the plan I present to you is better because it has been stress-tested by a room full of specialists who were all looking at the same data at the same time.

Research consistently supports this. Studies have shown that multidisciplinary tumor board review leads to changes in treatment recommendations in a meaningful percentage of cases — sometimes because imaging findings were underappreciated at initial evaluation, sometimes because a different treatment modality offers equivalent cure with less functional impact, and sometimes because a case that seemed straightforward turns out to be more complex on closer review. A 2017 analysis published in Head & Neck found that tumor board discussion resulted in a change in management in approximately 20% of head and neck cancer cases reviewed. [doi: 10.1002/hed.24662]

The tumor board also serves as a quality-check on the treatment plan. Because the recommendation is made collectively, no single physician's blind spot or training bias drives the decision. The medical oncologist will push back if chemotherapy is being added without clear evidence of benefit. The radiation oncologist will raise concerns if radiation fields risk significant toxicity to critical structures. I will raise concerns if a proposed non-surgical approach leaves a primary tumor that I believe will not respond adequately. That tension, resolved through open discussion, is the point.

What Happens After the Tumor Board

After your case is reviewed, I meet with you to explain the recommended treatment plan and the reasoning behind it. I will tell you what the tumor board discussed and what conclusions were reached. If there were meaningful alternative options considered, I will present those to you as well, along with my recommendation.

You are always part of this process. The tumor board recommendation is not a mandate — it is the best expert opinion available, and it is presented to you so that you can make an informed decision about your care. Some patients have personal priorities — preserving voice, avoiding a feeding tube, returning to work quickly — that appropriately influence how we weigh competing options. Those priorities matter, and they factor into the final plan.

The tumor board ensures that when we sit down together, the plan on the table has been reviewed by a team with the breadth of expertise your diagnosis demands.

Getting a Second Opinion

If you are newly diagnosed with head and neck cancer and your current treating team does not operate a formal multidisciplinary tumor board, that is worth knowing. Tumor board review is not a service every practice or every cancer center offers with the same regularity or depth. At a dedicated head and neck cancer program like ours at Aurora St. Luke's, weekly tumor board review is a standard part of the workflow — not an exception requested for difficult cases.

If you have questions about your diagnosis, your treatment plan, or whether your case has received multidisciplinary review, I am glad to see you for a consultation. Second opinions are a routine and welcome part of head and neck cancer care, and I always provide a thorough, independent assessment of the imaging, pathology, and treatment options.

To schedule a consultation, call my office at 414-649-3920.

Dr. Steven Sperry is a fellowship-trained head and neck surgeon specializing in head and neck cancer surgery and microvascular free flap reconstruction at Aurora St. Luke's Medical Center in Milwaukee, Wisconsin.